Advertisement

Journal of Inherited Metabolic Disease

, Volume 30, Issue 2, pp 239–247 | Cite as

Diagnosis of families with familial hypercholesterolaemia and/or Apo B-100 defect by means of DNA analysis of LDL-receptor gene mutations

  • K. Widhalm
  • A. Dirisamer
  • A. Lindemayr
  • G. Kostner
Original Article

Summary

Background: One major problem of using hypercholesterolaemia alone as a primary criterion for diagnosing familial hypercholesterolaemia (FH) is that 15–40% of relatives may be misdiagnosed because plasma lipid levels in FH heterozygotes overlap with those in the general population. Setting: General Hospital/University of Vienna, Department of Pediatrics, Outpatient lipid clinic. Methods: As a part of the MED-PED (make early diagnosis – prevent early death) project we are currently investigating children, adolescents and their relatives who are suspected to be affected with FH in our out-patient clinic for metabolic diseases using MED-PED inclusion criteria and confirming the diagnosis by means of DNA analysis. Patients: 263 patients with premature atherosclerosis and/or hypercholesterolaemia: 116 children (mean age 11.6 ± 4.1 years; 57 girls and 59 boys) and 147 adults (64 women, mean age 41.5 ± 13.7 years; 83 men, mean age 42.8 ± 10.8 years). Results: 119 patients with mutations have been detected; 56 children with either low density lipoprotein receptor (LDLR) and/or ApoB mutations (27 girls and 29 boys; mean total cholesterol (TC) 275 ± 71 mg/dl, triglycerides (TG) 101 ± 57 mg/dl, high-density lipoprotein cholesterol (HDL-C) 49 ± 12 mg/dl, low-density lipoprotein cholesterol (LDL-C) 198 ± 67 mg/dl) and one boy with a homozygous. LDLR mutation. A further 62 adults with LDLR and/or ApoB mutations were documented; 33 women (mean age 36.9 ± 11.1 years; mean TC 283 ± 76 mg/dl, TG 137 ± 78 mg/dl, HDL-C 55 ± 17 mg/dl, LDL-C 210 ± 67 mg/dl) and 29 men (mean age 45.0 ± 10.6 years; mean TC 301 ± 87 mg/dl, TG 163 ± 112 mg/dl, HDL-C 42 ± 12 mg/dl, LDL-C 233 ± 83 mg/dl). In 32 of these subjects (11 children (21%), 21 adults (42%)), serum lipid levels were lower than the diagnostic MED-PED limits adopted, so that they might have been misclassified without an additional DNA analysis. Conclusion: In our study, diagnosis of FH and related disorders (ApoB-100 defect) by means of conventional laboratory methods missed at least 21% in children and 42% in adults affected with LDLR and/or ApoB gene mutations. Genetic FH diagnosis provides a tool for specific diagnosis of mutation carrier status.

Keywords

Familial Hypercholesterolemia Serum Lipid Level Arterioscler Thromb Vasc Biol Familial Hypercholesterolemia Familial Hypercholesterolaemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

CVD

coronary heart disease

FH

familial hypercholesterolaemia

HDL-C

high-density lipoprotein cholesterol

LDL-C

low-density lipoprotein cholesterol

LDLR

low density lipoprotein receptor

MCI

myocardial infarction

MED-PED

make early diagnosis – prevent early death

TC

total cholesterol

TG

triglycerides

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Betard C, Kessling AM, Roy M, Davignon J (1996) Influence of genetic variability in the nondeletion LDL-receptor allele on phenotypic variation in French-Canadian familial hypercholesterolemia heterozygotes sharing ‘null’ LDL-receptor gene defect. Atherosclerosis 119: 43–55.PubMedCrossRefGoogle Scholar
  2. Betteridge DJ, Broome K, Durrington PN, et al (1991) Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 303: 893–896.CrossRefGoogle Scholar
  3. Coresh J, Beaty TH, Kwiterovich PO, Antonarakis S (1992) Pedigree and sib-pair linkage analysis suggest the apolipoproteinB gene is not the major gene influencing plasma apolipoproteinB levels. Am J Hum Genet 50: 1038–1045.PubMedGoogle Scholar
  4. Dallongeville J, Roy M, Leboeuf N, Xhignesse M, Davignon J, Lussier-Cacan S (1991) Apolipoprotein E polymorphism association with lipoprotein profile in endogenous hypertriglyceridemia and familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 11: 272–278.Google Scholar
  5. Davignon J, Roy M (1993) Familial hypercholesterolemia in French-Canadians: taking advantage of the presence of a “founder effect”. Am J Cardiol 72: 6D–10D.PubMedCrossRefGoogle Scholar
  6. Deeb S, Failor RA, Brown BG, et al (1992) Association of apolipoprotein B gene variants with plasma apoB and low density lipoprotein (LDL) cholesterol levels. Hum Genet 88: 463–470.PubMedCrossRefGoogle Scholar
  7. Ferrieres J, Sing CF, Roy M, Davignon J, Lussier-Cacan S (1994) Apolipoprotein E polymorphism and heterozygous familial hypercholesterolemia. Sex specific effects. Arterioscler Thromb Vasc Biol 14: 1553–1560.Google Scholar
  8. Ferrieres J, Lambert J, Lussier-Cacan S, Davignon J (1995) Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. Circulation 92: 290–295.PubMedGoogle Scholar
  9. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low density lipoprotein cholesterol in plasma cholesterol without use of preperative ultracentrifuge. Clin Chem 18: 499–502.PubMedGoogle Scholar
  10. Graham CA, McClean E, Ward AJM, et al (1999) Mutation screening and genotype:phenotype correlation in familial hypercholesterolaemia. Atherosclerosis 147: 309–316.PubMedCrossRefGoogle Scholar
  11. Hobbs HH, Brown MS, Goldstein JL (1992) Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1(6): 445–466.PubMedCrossRefGoogle Scholar
  12. Kessling AM, Seed M ,Taylor R, Wynn V, Humphries SE (1990) Rising cholesterol levels in children with familial hypercholesterolaemia. Biomed Pharmacother 44(7): 373–379.PubMedCrossRefGoogle Scholar
  13. Koivisto UM, Turtola H, Aalto-Setala K, et al (1990) The familial hypercholesterolemia (FH)-North Karelia mutation of the low density lipoprotein receptor gene deletes seven nucleotides of exon 6 and is a common cause of FH in Finland. J Clin Invest 90: 219–228.Google Scholar
  14. Koivisto PVI, Koivisto UM, Miettinen TA, Kontula K (1992) Diagnosis of heterozygous familial hypercholesterolemia: DNA analysis complements clinical examination and analysis of serum lipid levels. Arterioscler Thromb Vasc Biol 12: 584–592.Google Scholar
  15. Kotze MJ, Davis HJ, Bissbort S, Langenhoven E, Brusnicky J, Oosthuizen CJ (1993a) Intrafamilial variability in the clinical expression of familial hypercholesterolemia: importance of risk factor determination for genetic counselling. Clin Genet 43(6): 295–299.CrossRefGoogle Scholar
  16. Kotze MJ, De Villiers WSJ, Steyn K, et al (1993b) Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations. Arterioscler Thromb Vasc Biol 13: 1460–1468.Google Scholar
  17. Kwiterovich PO, Levy RI, Fredrickson DS (1973) Neonatal diagnosis of familial type II hyperlipoproteinemia. Lancet i: 118–122.CrossRefGoogle Scholar
  18. Lerman LS, Silverstein S (1987) Computational simulation of DNA melting and its application to denaturant gradient gel electrophoresis. Methods Enzymol 155: 482–501.PubMedCrossRefGoogle Scholar
  19. Loubster O, Marais AD, Kotze MJ, et al (1999) Founder mutations in the LDL receptor gene contribute significantly to the familial hypercholesterolemia phenotype in the indigenous South African population of mixed ancestry. Clin Genet 55: 340–345.CrossRefGoogle Scholar
  20. Mizuno K, Nakamura H, Ohashi Y, et al (2004) A randomized, open-label, comparative study of simvastatin plus diet versus diet alone on angiographic retardation of coronary atherosclerosis in adult Japanese patients: Japanese utilization of simvastatin therapy (JUST) study. Clin Ther 26: 878–888.PubMedCrossRefGoogle Scholar
  21. Myant NB, Gallagher JJ, Knight BL, et al (1991) Arterioscler Thromb Vasc Biol 11: 691–703.Google Scholar
  22. Myers RM, Lumelsky N, Lerman LS, Maniatis T (1986) Detection of single base substitutions in total genomic DNA. Nature 313: 495–498.CrossRefGoogle Scholar
  23. Nissen H, Hansen AB, Guldberg P, et al (1996) Phenotypic presentation of the FH-Cincinnati type 5 low density lipoprotein receptor mutation. Scand J Clin Lab Invest 56(1): 75–85.PubMedGoogle Scholar
  24. Nora JJ, Lortscher RM, Spangler RD, Bilheimer DW (1985) Familial hypercholesterolemia with “normal” cholesterol in obligate heterozygotes. Am J Med Genet 22(3): 585–591.PubMedCrossRefGoogle Scholar
  25. Sheffield VC, Cox DR, Lerman LS, Myers LM (1989) Attachment of a 40 base G+C rich sequence (GC-clamp) to genomic DNA fragments by the polymerase chain reaction results in improved detection of single base changes. Proc Natl Acad Sci USA 86: 232–236.PubMedCrossRefGoogle Scholar
  26. Sun XM, Patel DD, Knight BL, Soutar AK (1998) Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolaemia. Atherosclerosis 136: 175–185.PubMedCrossRefGoogle Scholar
  27. The MED-PED FH program (1995) Make early diagnosis, prevent early death from familial hypercholesterolemia. Med J Aust 162: 454–455.Google Scholar
  28. Torres AL, Moorjani S, Vohl MC, et al (1996) Heterozygous familial hypercholesterolemia in children: low-density lipoprotein receptor mutational analysis and variation in the expression of plasma lipoprotein—lipid concentrations. Atherosclerosis 126(1): 163–171.PubMedCrossRefGoogle Scholar
  29. Vohl MC, Moorjani S, Roy M, et al (1997) Geographic distribution of French-Canadian low-density lipoprotein receptor gene mutations in the Province of Quebec. Clin Genet 52: 1–6.PubMedCrossRefGoogle Scholar
  30. Vurio AF, Turtola H, Piilahti KM, Repo P, Kanninen T, Kontula K (1997) Familial hypercholesterolemia in the Finnish North Karelia: a molecular, clinical, and genealogical study. Arterioscler Thromb Vasc Biol 17: 3127–3138.Google Scholar
  31. Ward AJ, Kane MO, Nicholls DP, Young IS, Nevin NC, Graham CA (1996) A novel single base deletion in the LDLR gene (211delG): effect on serum lipid profiles and the influence of other genetic polymorphism in the ACE, APOE and APOB genes. Atherosclerosis 120: 83–91.PubMedCrossRefGoogle Scholar
  32. Williams RR, Hunt SC, Schumacher MC, et al (1993a) Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 72: 171–176.CrossRefGoogle Scholar
  33. Williams RR, Schumacher MC, Barlow GK, et al (1993b) Documented need for more effective diagnosis and treatment of familial hypercholesterolemia according to data from 502 heterozygotes in Utah. Am J Cardiol 72: 18D–24D.CrossRefGoogle Scholar
  34. WHO (1997) Human Genetics Programme. Report of a WHO Consultation: Familial Hypercholesterolemia (FH). Geneva: WHO.Google Scholar
  35. WHO (1998) Press release WHO/62, 4 September 1998.Google Scholar
  36. van Aalst-Cohen ES, Jansen AC, Tanck MW, et al (2006) Diagnosing familial hypercholesterolaemia: the relevance of genetic testing. Eur Heart J 27: 2240–2246.PubMedCrossRefGoogle Scholar

Copyright information

© SSIEM and Springer 2007

Authors and Affiliations

  • K. Widhalm
    • 1
  • A. Dirisamer
    • 1
    • 2
  • A. Lindemayr
    • 1
  • G. Kostner
    • 3
  1. 1.Department of PediatricsUniversity of ViennaViennaAustria
  2. 2.Department of RadiologyUniversity of ViennaViennaAustria
  3. 3.Department of Medical BiochemistryUniversity of GrazGrazAustria

Personalised recommendations